SeaStar Medical’s Chief Medical Officer to Showcase QUELIMMUNE at PPETS 2026

  • SeaStar Medical’s Chief Medical Officer, Kevin Chung, M.D., will present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026 on October 6, 2026.
  • The presentation will highlight QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI).
  • QUELIMMUNE has shown a 77% survival rate in clinical trials, representing a 50% reduction in mortality compared to historical data.
  • The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU.

SeaStar Medical’s presentation at PPETS 2026 underscores the growing recognition of its QUELIMMUNE therapy in treating critically ill pediatric patients with AKI. The company’s focus on immunomodulation through its Selective Cytopheretic Device (SCD) therapy positions it at the forefront of addressing destructive hyperinflammation, a critical unmet need in acute kidney and cardiovascular diseases. The NEUTRALIZE-AKI trial and post-approval data will be key in validating the therapy’s long-term efficacy and market potential.

Clinical Validation
Whether QUELIMMUNE’s survival rate improvements can be sustained in broader clinical use and post-approval surveillance.
Regulatory Pathway
The pace at which SeaStar Medical can secure additional FDA approvals for the SCD therapy’s broader applications.
Market Adoption
How quickly QUELIMMUNE gains commercial acceptance among pediatric nephrologists and intensivists.